Navigation Links
ULURU Inc. Announces the Expansion of the International Marketing Network

ADDISON, Texas, Dec. 11, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), today announced the expansion of the Altrazeal® international marketing network. Agreements have been signed granting the exclusive marketing and distribution rights for Altrazeal® in Italy, Spain and Greece.

Commenting on the extension of the international marketing network, Helmut Kerschbaumer, Managing Director of Altrazeal GmbH, stated, "These agreements are an important step in the commercialization of Altrazeal®, as Italy and Spain are major markets in the European Union. Positive clinical experiences have already been generated and we are now working to expeditiously launch Altrazeal® into these markets. We continue to execute on our objective to appoint highly qualified marketing partners in all countries throughout our licensed territory."

Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.

Kerry P. Gray, President and CEO of ULURU Inc., stated, "Great progress has been made to establish a global marketing network for Altrazeal®. As Altrazeal represents a cost effective approach for the treatment of acute and chronic wounds there is an opportunity to establish a truly global marketing network. We are working closely with Altrazeal GmbH to have Altrazeal® available for marketing in these countries as quickly as possible."

About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc™ transmucosal delivery system.  For further information about ULURU Inc., please visit our website at  For further information about Altrazeal®, please visit

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended.  These statements are subject to numerous risks and uncertainties, including but not limited to the launch of Altrazeal® in the territory, the commercial potential of Altrazeal® and the demonstration of cost savings and clinical benefits, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by us with the Securities and Exchange Commission.

Contact: Company
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
(214) 905-5145

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ULURU Inc. Reports Third Quarter 2013 Financial Results
2. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Third Quarter Ended September 30, 2013
3. ULURU Inc. Completes Redemption Of Preferred Stock
4. ULURU Inc. Reports Second Quarter 2013 Financial Results
5. ULURU Inc. Announces Conference Call To Discuss Financial Results For The Second Quarter Ended June 30, 2013
6. ULURU Inc. Reports First Quarter 2013 Financial Results
7. ULURU Inc. Announces Conference Call To Discuss Financial Results For The First Quarter Ended March 31, 2013
8. ULURU Inc. Reports Financial Results For Fourth Quarter And Year Ending December 31, 2012
9. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2012 and to Provide a Business Update
10. ULURU Inc. Business Update And Outlook
11. ULURU Inc. Announces Closing Of $440,000 Private Placement
Post Your Comments:
(Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... "I struggled for years with pain every day. I ... would love to do, I missed. We moved back home from living out of ... first. They have changed my life drastically. I love all of the people involved ...
(Date:11/29/2015)... ... , ... NewsWatch featured X-wing as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... future because flying cars are about to become a reality. Where’s the idea from? ...
(Date:11/29/2015)... ... ... While conventional walkers afford considerable help with mobility, their design does not allow ... from Uniontown, Pa., has found a way to address those needs. , He developed ... to improve the user’s quality of life. To begin with, this improved mobility aid ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic ... distortion effect tool designed specially for Final Cut Pro X. FCPX ... with the easy-to-use modification controls. Destoying and creating chaotic distortion is now quick ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated ... announce their December, 2015, featured apartment community: Epic. In showcasing this featured apartment community ... the tight Bay Area rental market to efficiently find housing suitable to their needs ...
Breaking Medicine News(10 mins):